Switch theme
Sign up to access all valuation multiples
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma’s proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
2008
46
LTM Revenue $20.0M
Last FY EBITDA -$58.8M
$2.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CARISMA Therapeutics has a last 12-month revenue (LTM) of $20.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, CARISMA Therapeutics achieved revenue of $19.6M and an EBITDA of -$58.8M.
CARISMA Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CARISMA Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $20.0M | XXX | $19.6M | XXX | XXX | XXX |
| Gross Profit | $20.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$58.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -300% | XXX | XXX | XXX |
| EBIT | -$43.5M | XXX | -$62.2M | XXX | XXX | XXX |
| EBIT Margin | -217% | XXX | -317% | XXX | XXX | XXX |
| Net Profit | -$42.5M | XXX | -$60.5M | XXX | XXX | XXX |
| Net Margin | -212% | XXX | -308% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CARISMA Therapeutics's stock price is $0.
CARISMA Therapeutics has current market cap of $8.0M, and EV of $2.6M.
See CARISMA Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.6M | $8.0M | XXX | XXX | XXX | XXX | $-1.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CARISMA Therapeutics has market cap of $8.0M and EV of $2.6M.
CARISMA Therapeutics's trades at 0.1x EV/Revenue multiple, and -0.0x EV/EBITDA.
Equity research analysts estimate CARISMA Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CARISMA Therapeutics has a P/E ratio of -0.2x.
See valuation multiples for CARISMA Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.0M | XXX | $8.0M | XXX | XXX | XXX |
| EV (current) | $2.6M | XXX | $2.6M | XXX | XXX | XXX |
| EV/Revenue | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.0x | XXX | XXX | XXX |
| EV/EBIT | -0.1x | XXX | -0.0x | XXX | XXX | XXX |
| EV/Gross Profit | 0.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.2x | XXX | -0.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCARISMA Therapeutics's last 12 month revenue growth is -49%
CARISMA Therapeutics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $1.8M for the same period.
CARISMA Therapeutics's rule of 40 is -625% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CARISMA Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CARISMA Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -49% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -300% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -625% | XXX | -348% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 304% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 417% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CARISMA Therapeutics acquired XXX companies to date.
Last acquisition by CARISMA Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . CARISMA Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CARISMA Therapeutics founded? | CARISMA Therapeutics was founded in 2008. |
| Where is CARISMA Therapeutics headquartered? | CARISMA Therapeutics is headquartered in United States of America. |
| How many employees does CARISMA Therapeutics have? | As of today, CARISMA Therapeutics has 46 employees. |
| Who is the CEO of CARISMA Therapeutics? | CARISMA Therapeutics's CEO is Mr. Steven Kelly. |
| Is CARISMA Therapeutics publicy listed? | Yes, CARISMA Therapeutics is a public company listed on NAS. |
| What is the stock symbol of CARISMA Therapeutics? | CARISMA Therapeutics trades under CARM ticker. |
| When did CARISMA Therapeutics go public? | CARISMA Therapeutics went public in 2023. |
| Who are competitors of CARISMA Therapeutics? | Similar companies to CARISMA Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of CARISMA Therapeutics? | CARISMA Therapeutics's current market cap is $8.0M |
| What is the current revenue of CARISMA Therapeutics? | CARISMA Therapeutics's last 12 months revenue is $20.0M. |
| What is the current revenue growth of CARISMA Therapeutics? | CARISMA Therapeutics revenue growth (NTM/LTM) is -49%. |
| What is the current EV/Revenue multiple of CARISMA Therapeutics? | Current revenue multiple of CARISMA Therapeutics is 0.1x. |
| Is CARISMA Therapeutics profitable? | Yes, CARISMA Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
